Stocktoria

Harmony Biosciences Holdings, Inc. HRMY

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-08-19
Chart by TradingView
6/9
Piotroski F — financial health
7.17
Altman Z″ — distress risk · safe
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$868.5M$714.7M$582.0M$437.9M$305.4M
Gross profit$670.1M$557.9M$460.8M$354.4M$249.9M
Operating income$208.5M$190.8M$192.0M$120.2M$87.5M
Net income$158.7M$145.5M$128.9M$181.5M$34.6M
Operating cash flow$348.2M$219.8M$219.4M$144.5M$98.6M
Free cash flow$347.9M$218.7M$219.1M$144.3M$98.3M
Total assets$1.3B$999.2M$811.4M$673.9M$433.4M
Total liabilities$401.4M$340.0M$344.5M$271.0M$246.9M
Shareholders' equity$870.2M$659.2M$467.0M$402.8M$186.5M
Ratios
Gross margin77.2%78.1%79.2%80.9%81.8%
Operating margin24.0%26.7%33.0%27.4%28.7%
Net margin18.3%20.4%22.1%41.4%11.3%
FCF margin40.1%30.6%37.6%33.0%32.2%
Return on assets12.5%14.6%15.9%26.9%8.0%
Return on equity18.2%22.1%27.6%45.0%18.5%
Debt / equity0.19×0.27×0.38×0.48×1.02×
Current ratio3.603.312.755.075.29
Revenue growth21.5%22.8%32.9%43.4%91.2%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC1,077,371$30.2M
Bridgewater Associates, LP251,506$7.0M

Why these scores methodology →

Piotroski F-score: 6/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 7.17 (safe)

  • Working capital / assets 0.515
  • Retained earnings / assets 0.127
  • EBIT / assets 0.164
  • Equity / liabilities 2.168

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001802665 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.